Group 1: Company Operations - The company has successfully completed a 1.5 times expansion of its coenzyme Q10 raw material production line, with new fermentation tanks successfully tested and currently maintaining a strong production and sales momentum [2][3] - The price of Vitamin A has decreased due to market fluctuations, while DHA products have improved competitiveness through technological upgrades and market promotion, laying a solid foundation for future market expansion [2][3] - Other raw material products such as astaxanthin and Vitamin K2 are showing significant positive trends [3] Group 2: Market Expansion and Product Development - The company's health food finished product business is expanding well in the domestic market, benefiting from the rapid development of the domestic health consumption industry [3] - The overseas subsidiary VitaBest's soft capsule production line is under construction and is expected to be operational in the second half of the year; Zipfizz functional beverages will introduce four new flavors and a new "YOU" ready-to-drink product series [3] Group 3: Regulatory and Market Challenges - The current tariff rate for coenzyme Q10, Vitamin A, Vitamin D3, and Vitamin K2 exported to the U.S. is 20%. The company has mitigated the tariff impact by raising sales prices or having downstream customers bear the tariff costs; the sales proportion of vitamin products in the U.S. is small, limiting the overall impact [3] Group 4: Marketing Strategies - The company plans to develop marketing strategies for end-nutrition health products based on industry characteristics, market demand, brand positioning, and resource integration capabilities, utilizing market insights and data-driven approaches to create market-leading products [3] Group 5: Synthetic Biology Applications - The company employs synthetic biology as a foundational technology for the large-scale production of various raw material products, including coenzyme Q10, NMN, NADH, Vitamin K2, nattokinase, PQQ, SAMe, DHA, and ARA, while also exploring new products such as astaxanthin, algal oil EPA, glutathione, inositol, calcium pantothenate, and biological sweeteners [3]

Core Viewpoint - The company reported strong financial performance in 2024 and Q1 2025, driven by increased sales of Coenzyme Q10 and a rebound in Vitamin A market prices, indicating a positive growth trajectory in the health supplement sector [1][4]. Financial Performance - In 2024, the company achieved revenue of 3.24 billion yuan (up 4.43% year-on-year), with a net profit attributable to shareholders of 342 million yuan (up 23.59% year-on-year) and a non-recurring net profit of 339 million yuan (up 20.80% year-on-year) [1]. - For Q1 2025, the company reported revenue of 827 million yuan (up 11.31% year-on-year), a net profit of 122 million yuan (up 71.97% year-on-year), and a non-recurring net profit of 119 million yuan (up 70.03% year-on-year) [1][4]. Product Performance - Revenue breakdown for 2024 shows that health supplements, Coenzyme Q10 series, Vitamin A series, and other products generated revenues of 1.964 billion, 726 million, 273 million, and 277 million yuan respectively, with year-on-year growth rates of +3.67%, -1.11%, +27.17%, and +6.87% [1]. - Gross profit contributions from product lines were 55.47% for health supplements, 28.02% for Coenzyme Q10, 7.17% for Vitamin A, and 9.33% for other products, with Vitamin A's gross margin increasing significantly by 36.74 percentage points [2]. Capacity Expansion and Globalization - The company is actively expanding production capacity, with Coenzyme Q10 production lines operating at full capacity and a 1.5 times expansion project completed, increasing annual capacity to 920 tons [3]. - The company has successfully acquired Activ Nutritional, LLC, enhancing its global presence and brand portfolio, while also launching new functional beverage products [3]. Cost Management and Efficiency - In Q1 2025, the company achieved a gross margin of 41.74% and a net profit margin of 14.72%, with significant improvements in management expense ratios [4]. - The company is focusing on optimizing supply chains and reducing costs through better governance of its overseas subsidiary, VitaBest [4]. Technological Advancements - The company is leveraging synthetic biology for the large-scale production of raw materials, achieving lower costs for Coenzyme Q10 and obtaining patents for high-yield production methods [5]. - The company aims to continue developing high-potential products using core technologies such as synthetic biology and microbial fermentation [5]. Investment Outlook - The company is positioned as a leader in the Coenzyme Q10 market with a market share of approximately 50% as of March 2025, and is expected to achieve revenues of 3.672 billion, 4.13 billion, and 4.563 billion yuan from 2025 to 2027, with corresponding net profits of 448 million, 540 million, and 629 million yuan [6].

Summary of Key Points Core Viewpoint - As of May 16, the total market financing balance decreased to 1.79 trillion yuan, indicating a slight reduction in investor activity in the market [1]. Company and Industry Analysis - The financing balance in the Shanghai market was 907.43 billion yuan, down by 0.92 billion yuan, while the Shenzhen market's balance was 882.06 billion yuan, also down by 0.92 billion yuan. The North Exchange's financing balance decreased to 5.38 billion yuan, down by 0.038 billion yuan [1]. - On May 16, a total of 1,712 stocks received net financing purchases, with 257 stocks having net purchases exceeding 10 million yuan. Notably, 22 stocks had net purchases over 50 million yuan [1]. - The top three stocks by net financing purchases on May 16 were: - China Merchants Bank: 170.42 million yuan - Tonghua Golden Horse: 167.08 million yuan - China Ping An: 136.61 million yuan [2]. - The industries with the highest concentration of stocks receiving net financing purchases over 50 million yuan included automotive, basic chemicals, and food and beverage, each with three stocks listed [1]. - The average ratio of financing balance to circulating market value for stocks with significant net purchases was 4.01%, with Dongtu Technology having the highest ratio at 9.79% [2]. - The financing net purchase rankings on May 16 highlighted several stocks, including: - Dongtu Technology: 8.04 million yuan, 7.58% increase - Tonghua Golden Horse: 16.71 million yuan, 2.45% increase - BYD: 9.85 million yuan, 3.28% increase [2][3].

Core Viewpoint - The chairman of Kingdawei, Jiang Bin, emphasizes that effective market value management is achieved through solid business practices, good products, and returning profits to shareholders, society, and employees [5]. Financial Performance - In 2024 and Q1 of this year, Kingdawei achieved a net profit attributable to shareholders of approximately 340 million yuan and 120 million yuan, representing a year-on-year growth of about 23.6% and 72% respectively [5]. - The overall sales gross margin for Kingdawei in Q1 2025 was approximately 41.7% [7]. Product Margins and Competitive Advantage - The gross margins for Kingdawei's Vitamin A, Coenzyme Q10, and nutritional supplements in 2024 were 32.8%, 48.2%, and 35.2% respectively [7]. - Kingdawei leads its competitors in Coenzyme Q10 by 30 to 40 percentage points in gross margin, making it difficult for rivals to catch up in the next three to five years [7]. - The company aims to reduce costs for astaxanthin production using synthetic biology to one-fifth of traditional methods [8]. Synthetic Biology and Innovation - Jiang Bin highlights that the innovation in synthetic biology will usher in a new era of biological manufacturing, which is a disruptive innovation compared to traditional methods [8]. - The production of astaxanthin through synthetic biology allows for controlled quality and reduced costs, making it feasible to enter the high-end aquaculture feed market [8]. Expansion and Production Capacity - Kingdawei is the largest global producer of Coenzyme Q10, with an expanded production capacity of 920 tons per year after completing a 1.5 times expansion project [13]. - The company plans to further increase its production capacity to 1,200 tons and eventually to 1,500 tons, focusing on maintaining a competitive edge through capacity expansion rather than price increases [14]. Global Market Strategy - Kingdawei's overseas sales revenue in 2024 was approximately 2.57 billion yuan, accounting for nearly 80% of total revenue [14]. - The company is expanding its presence in the U.S. market through its subsidiary VitaBest, which is expected to enhance supply chain responsiveness and operational efficiency [17]. Brand Development and Market Penetration - Kingdawei owns several brands in the U.S., including Doctor's Best and Zipfizz, and aims to increase SKU offerings to penetrate major retail channels like Costco [18]. - The acquisition of Viactiv, a well-known calcium supplement brand, further enriches Kingdawei's product matrix targeting women [18].

Group 1 - The concept of ergot sulfur has gained popularity, leading to significant stock price movements among related companies, with some experiencing a daily limit increase [1][3] - Kelong Pharmaceutical has been actively promoting ergot sulfur, with its chairman showcasing the product's potential in an advertisement, which has contributed to the surge in related stocks [1][2] - Several companies have responded to investor inquiries regarding their involvement with ergot sulfur, indicating that the revenue from products containing this ingredient is currently low and has minimal impact on overall performance [3] Group 2 - Kelong Pharmaceutical has been focusing on the health industry for seven years, emphasizing the commercialization of ergot sulfur as a key growth factor [2] - Other companies, such as Haizheng Pharmaceutical and Wanbang Pharmaceutical, are also exploring the potential applications of ergot sulfur, with ongoing research and development efforts [3]

证券代码：002626 证券简称：金达威 公告编号：2025-043 厦门金达威集团股份有限公司关于 公司董事会完成换届选举并聘任高级管理人员及其他人员的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 其中宗耕先生为第九届董事会提名委员会主任。 一、第九届董事会成员情况 非独立董事：江斌先生（董事长）、顾卫华先生（副董事长）、陈佳良先 生、洪航先生、徐肖特先生、吴轶先生（职工代表董事） 独立董事：王大宏先生、王肖健先生、宗耕先生 公司董事会中兼任高级管理人员以及由职工代表担任的董事人数总计未超 过公司董事总数的二分之一；独立董事占董事会成员的比例不低于三分之一， 且任职资格和独立性已经深圳证券交易所备案审核无异议。公司第九届董事会 任期自 2025 年第一次临时股东大会审议通过之日起三年。 二、第九届董事会各专门委员会委员情况 公司第九届董事会下设四个专门委员会：战略委员会、提名委员会、薪酬与 考核委员会、审计委员会，具体情况为： 员，其中江斌先生为第九届董事会战略委员会主任。 厦门金达威集团股份有限公司（以下简称"公司"）于 2025 年 5 月 15 ...

邮箱：jie.lin@kingdomway.com 地址：福建省厦门市海沧新阳工业区阳光西路 299 号 特此公告。 证券代码：002626 证券简称：金达威 公告编号：2025-044 厦门金达威集团股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 厦门金达威集团股份有限公司（以下简称"公司"）于 2025 年 5 月 15 日召 开第九届董事会第一次会议，审议通过《关于聘任公司证券事务代表的议案》， 同意聘任林洁女士为证券事务代表（简历附后）。林洁女士已取得深圳证券交易 所颁发的《上市公司董事会秘书培训证明》，具备担任证券事务代表所需的专业 知识和履职能力，符合《中华人民共和国公司法》《深圳证券交易所股票上市规 则》等相关法律法规和规范性文件的规定。 林洁女士的联系方式如下： 电话：0592-3781888 厦门金达威集团股份有限公司 董 事 会 二〇二五年五月十五日 附件：林洁女士简历 林洁女士：1997 年 12 月出生，中国国籍，本科学历。2022 年 6 月至今就职 于厦门金达威集团股份有限公司证券事务部，已取得深圳证券交易所颁发的《上 ...

厦门金达威集团股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 厦门金达威集团股份有限公司（以下简称"公司"）第九届董事会第一次会 议于 2025 年 5 月 15 日在厦门市海沧区公司五层会议室以现场结合通讯表决的方 式召开。经全体董事一致同意，豁免本次董事会提前通知期限。本次会议由全体 董事一致推举江斌先生主持，公司董事会成员应到九人，实际参加表决人数九人。 公司副总经理、财务总监等高级管理人员候选人亦列席了本次会议。本次会议的 召集、召开符合《中华人民共和国公司法》和公司章程的有关规定。 经与会董事认真审议，本次会议以现场结合通讯表决的方式审议通过了以下 议案： 一、 会议以 9 票同意、0 票反对、0 票弃权的表决结果审议通过《关于选举 第九届董事会董事长、副董事长的议案》 选举江斌先生为公司第九届董事会董事长、顾卫华先生为第九届董事会副董 事长，任期自本次会议审议通过之日起至第九届董事会届满之日止。 证券代码：002626 证券简称：金达威 公告编号：2025-041 具体内容详见公司于同日在巨潮资讯网（www.cninfo.com.cn ...

证券代码：002626 证券简称：金达威 公告编号：2025-042 厦门金达威集团股份有限公司 特此公告。 关于指定董事、副总经理兼财务总监代行董事会秘书职责的公告 厦门金达威集团股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 董 事 会 鉴于厦门金达威集团股份有限公司（以下简称"公司"）董事会秘书洪彦女 士任期已满，为保证公司各项工作的正常开展，公司董事会指定公司董事、副总 经理兼财务总监洪航先生自公告之日起代行董事会秘书职责。 洪航先生的联系方式如下： 电话：0592-3781761、0592-3781765 邮箱：honghang@kingdomway.com 地址：福建省厦门市海沧新阳工业区阳光西路 299 号 二〇二五年五月十五日 ...

关于聘任公司证券事务代表的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 证券代码：002626 证券简称：金达威 公告编号：2025-044 厦门金达威集团股份有限公司 邮箱：jie.lin@kingdomway.com 地址：福建省厦门市海沧新阳工业区阳光西路 299 号 特此公告。 厦门金达威集团股份有限公司 厦门金达威集团股份有限公司（以下简称"公司"）于 2025 年 5 月 15 日召 开第九届董事会第一次会议，审议通过《关于聘任公司证券事务代表的议案》， 同意聘任林洁女士为证券事务代表（简历附后）。林洁女士已取得深圳证券交易 所颁发的《上市公司董事会秘书培训证明》，具备担任证券事务代表所需的专业 知识和履职能力，符合《中华人民共和国公司法》《深圳证券交易所股票上市规 则》等相关法律法规和规范性文件的规定。 林洁女士的联系方式如下： 电话：0592-3781888 董 事 会 二〇二五年五月十五日 附件：林洁女士简历 林洁女士：1997 年 12 月出生，中国国籍，本科学历。2022 年 6 月至今就职 于厦门金达威集团股份有限公司证券事务部 ...